Calidi Biotherapeutics (CLDI) Beginning Cash Balance (2025)
Calidi Biotherapeutics' quarterly Beginning Cash Balance came in at $375000.0 in Q3 2025, little changed quarter-over-quarter from $375000.0 in Q2 2025.
Calidi Biotherapeutics has reported Beginning Cash Balance for 1 years, with the latest figure at $375000.0 in Q3 2025.
- For the quarter ending Q3 2025, Beginning Cash Balance changed N/A year-over-year to $375000.0; the trailing twelve-month figure through Dec 2025 stood at $2.0 million (changed N/A YoY), and the FY2025 full-year result was $2.0 million, changed N/A from the prior year.
- Beginning Cash Balance for Q3 2025 stood at $375000.0, roughly flat from $375000.0 in the prior quarter.
- The five-year high for Beginning Cash Balance was $1.2 million in Q1 2025, with the low at $375000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Calidi Biotherapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 375,000.00 |
| Sep 30, 2025 | 375,000.00 |
| Jun 30, 2025 | 375,000.00 |
| Jun 30, 2025 | 375,000.00 |
| Mar 31, 2025 | 1.25 Mn |
| Mar 31, 2025 | 1.25 Mn |